Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the Phase 3 INSPIRE and COMMAND Studies
Gastroenterol Hepatol (N Y)
.
2024 Jul;20(7 Suppl 6):11-13.
PMID:
39193121
PMCID:
PMC11345978
No abstract available